RU2011109880A - METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION - Google Patents
METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION Download PDFInfo
- Publication number
- RU2011109880A RU2011109880A RU2011109880/10A RU2011109880A RU2011109880A RU 2011109880 A RU2011109880 A RU 2011109880A RU 2011109880/10 A RU2011109880/10 A RU 2011109880/10A RU 2011109880 A RU2011109880 A RU 2011109880A RU 2011109880 A RU2011109880 A RU 2011109880A
- Authority
- RU
- Russia
- Prior art keywords
- ube2c
- diagnosis
- bladder cancer
- protein
- real
- Prior art date
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
1. Способ диагностики рака мочевого пузыря методом ПЦР в режиме реального времени, включающий получение биоматериала и выделение РНК, синтез кДНК на матрице РНК, нормирование концентрации кДНК UBE2C по контрольному гену, проведение количественной ПЦР-амплификации фрагмента гена UBE2C и проведение диагностики путем определения количества амплифицированного фрагмента ДНК UBE2C для образца биоматериала. ! 2. Набор для диагностики рака мочевого пузыря по п.1 методом ПЦР в реальном времени, включающий праймеры с последовательностью SEQ ID NO: 1 и 2 при их молярном соотношении 1:1. ! 3. Способ диагностики рака мочевого пузыря методом иммуноферментного анализа, включающий получение образцов мочи и крови от пациента, выделение смеси белковых компонентов мочи и крови, проведение реакции иммуноферментного анализа с моноклональными и/или поликлональными антителами и/или их фрагментами против рекомбинантного белка UBE2C и/или его уникальных фрагментов длиной свыше 8 аминокислот и проведение диагностики путем определения содержания белка UBE2C в исследуемых образцах. 1. A method for the diagnosis of bladder cancer by real-time PCR, including biomaterial production and RNA isolation, cDNA synthesis on an RNA matrix, normalization of the concentration of UBE2C cDNA by the control gene, quantitative PCR amplification of a fragment of the UBE2C gene and diagnosis by determining the amount of amplified UBE2C DNA fragment for a biomaterial sample. ! 2. The kit for the diagnosis of bladder cancer according to claim 1 by real-time PCR, including primers with the sequence of SEQ ID NO: 1 and 2 with a molar ratio of 1: 1. ! 3. A method for the diagnosis of bladder cancer by enzyme immunoassay, which includes obtaining urine and blood samples from a patient, isolating a mixture of protein components of urine and blood, conducting an enzyme immunoassay reaction with monoclonal and / or polyclonal antibodies and / or fragments thereof against recombinant protein UBE2C and / or its unique fragments with a length of more than 8 amino acids and conducting diagnostics by determining the content of UBE2C protein in the studied samples.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011109880/10A RU2468088C1 (en) | 2011-03-16 | 2011-03-16 | Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011109880/10A RU2468088C1 (en) | 2011-03-16 | 2011-03-16 | Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011109880A true RU2011109880A (en) | 2012-09-27 |
RU2468088C1 RU2468088C1 (en) | 2012-11-27 |
Family
ID=47077900
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2011109880/10A RU2468088C1 (en) | 2011-03-16 | 2011-03-16 | Method of estimating efficiency of therapy urinary bladder cancer in humans by method of immunofermentative analysis |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2468088C1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111323585A (en) * | 2020-02-27 | 2020-06-23 | 北京健平金星生物科技有限公司 | Preparation method of nuclear matrix protein 22 enzyme-linked immunoassay kit and kit |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2641170C1 (en) * | 2017-08-15 | 2018-01-16 | Олег Борисович Лоран | Method for bladder cancer course prediction |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2003196A3 (en) * | 2003-06-09 | 2009-01-07 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
-
2011
- 2011-03-16 RU RU2011109880/10A patent/RU2468088C1/en not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111323585A (en) * | 2020-02-27 | 2020-06-23 | 北京健平金星生物科技有限公司 | Preparation method of nuclear matrix protein 22 enzyme-linked immunoassay kit and kit |
Also Published As
Publication number | Publication date |
---|---|
RU2468088C1 (en) | 2012-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2663724C2 (en) | Methods for determining patient's susceptibility to nosocomial infection and predicting development of a septic syndrome | |
Shiiki et al. | Association between saliva PSA and serum PSA in conditions with prostate adenocarcinoma | |
DE602006012995D1 (en) | BREAST CANCER DIAGNOSTIC PROCEDURE | |
RU2013113314A (en) | METHODS FOR IDENTIFICATION OF ANTIBODIES AGAINST HE4 AND METHODS FOR DIAGNOSTIC AND / OR FORECASTING CONDITIONS ASSOCIATED WITH EXPRESS HE4 CELLS | |
JP2013536442A5 (en) | ||
WO2018210201A1 (en) | Molecular marker, kit and application for use in early diagnosis and prediction of sepsis as complication of acute kidney injury | |
WO2012163263A1 (en) | Reagents and methods for prrsv detection | |
JP2008523398A (en) | CD99 as a target / marker of insulin resistance | |
EP1951891A4 (en) | Cancer antigen mage-a9 and uses thereof | |
EP3998273A1 (en) | Methods for using exosomes to monitor transplanted organ status | |
CN113684317B (en) | Ultra-sensitive rapid detection and identification system for B type and C type hepatitis B virus based on CRISPR-Cas12B | |
CN111217912B (en) | Antibody against PG II and application thereof | |
ES2633732T3 (en) | Procedure and kit to determine in vitro the immune status of an individual | |
RU2011109880A (en) | METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONBECOMMARKER UBE2C (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
RU2011109883A (en) | DIAGNOSIS METHOD FOR BLADDER CANCER USING THE KIFC1 ONCOM MARKER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
CN109709328B (en) | Diagnostic marker for ovarian cancer and application thereof | |
RU2011109882A (en) | METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE ONCOMARKER ATR6V1C1 (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
KR102525734B1 (en) | Arteriosclerosis and cancer detection method using deoxyhypusine synthase gene as indicator | |
RU2011109879A (en) | METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING ONCOM MARKER PRC1 (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
CN108715848A (en) | Applications of the transcription factor CEBP α as the transcription factor of Kiss1 promoter regions | |
JP2012503634A5 (en) | ||
RU2011103094A (en) | METHOD FOR DIAGNOSTIC OF BLADDER CANCER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
RU2011109878A (en) | METHOD FOR DIAGNOSTIC OF BLADDER CANCER USING THE NUSAPI ONCOMARKER (OPTIONS) AND KIT FOR ITS IMPLEMENTATION | |
US20150219662A1 (en) | Use of protein line-1 orf-1 as a biomarker for cancer | |
CN104450712B (en) | The sequence of oligonucleotides aglucon V4 2 of specific recognition Vasorin (VASN) albumen a kind of and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20160317 |